Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04152018
Other study ID # C3891001
Secondary ID 2020-004009-29
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date November 13, 2019
Est. completion date August 30, 2024

Study information

Verified date April 2024
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 (Integrin alpha-V/beta-8 Antagonist) in patients with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434 in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination Expansion will enroll participants into 3 cohorts at doses determined from Part 1B in order to further evaluate the safety of PF-06940434 in combination with anti-PD-1.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 85
Est. completion date August 30, 2024
Est. primary completion date August 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histological or cytological diagnosis of SCCHN, RCC (clear cell and papillary cell), ovarian, gastric, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma, or urothelial cancer. Part 2: - Arm A SCCHN: - Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx. - PDL-1 expression positive and CPS =1. No prior systemic therapy administered in the recurrent or metastatic setting (except for systemic therapy given as part of a multimodal treatment for locally advanced disease). - Arm B RCC (clear cell): - 1 or 2 prior lines of therapy including PD-L1/PD-1 immunotherapy in combination or sequentially with antiangiogenic directed treatment - Adequate bone marrow, kidney and liver function. - Performance status of 0 or 1. Exclusion Criteria: - Participant disease status is suitable for local therapy administered with curative intent. - Hypertension that cannot be controlled by medications. - Active or prior autoimmune disease - Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Hepatitis B, Hepatitis C, and known Human Immunodeficiency Virus infection or Acquired Immunodeficiency Syndrome-related illness

Study Design


Intervention

Drug:
PF-06940434
PF-06940434 is given intravenously (IV) every 2 or 4 weeks in a 28 day cycle or every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated
PF-06801591
PF-06801591 will be administered subcutaneously on Day 1 of each 28 day cycle or Day 1 of each 21 day cycle.

Locations

Country Name City State
Australia Liverpool Hospital Liverpool New South Wales
Australia Southern Medical Day Care Centre Wollongong New South Wales
Korea, Republic of Asan Medical Center Seoul Seoul-teukbyeolsi [seoul]
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Slovakia Narodny ustav srdcovych a cievnych chorob, a.s. Bratislava
Slovakia Onkologicky ustav sv. Alzbety, s.r.o. Bratislava
Slovakia Univerzitna nemocnica Bratislava Bratislava
Slovakia MR Poprad s.r.o. Komárno
Slovakia KARDIO, s.r.o. Poprad
Slovakia MR Poprad s.r.o. Poprad
Slovakia Nemocnica Poprad a.s. Poprad
Slovakia Nemocnica Poprad a.s. Poprad
Slovakia POKO Poprad, s.r.o., Ambulancia klinickej onkologie Poprad
Taiwan National Cheng Kung University Hospital Tainan
Taiwan National Taiwan University Hospital Taipei
Taiwan Taipei Veterans General Hospital Taipei
United States Greenebaum Comprehensive Cancer Center Baltimore Maryland
United States University of Maryland Greenebaum Comprehensive Cancer Center Baltimore Maryland
United States Siteman Cancer Center - West County Creve Coeur Missouri
United States Duke Univ. Medical Center/Duke Cancer Center Durham North Carolina
United States Investigational Chemotherapy Service Durham North Carolina
United States Siteman Cancer Center - North County Florissant Missouri
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Monter Cancer Center Lake Success New York
United States R.J. Zuckerberg Cancer Center Lake Success New York
United States Ronald Reagan UCLA Medical Center Los Angeles California
United States UCLA Hematology Oncology Los Angeles California
United States UCLA Hematology/Oncology Los Angeles California
United States Barnes-Jewish Hospital Saint Louis Missouri
United States Siteman Cancer Center - North County Saint Louis Missouri
United States Siteman Cancer Center - South County Saint Louis Missouri
United States Washington University School of Medicine Siteman Cancer Center Saint Louis Missouri
United States Siteman Cancer Center - St. Peters Saint Peters Missouri
United States NEXT Oncology San Antonio Texas
United States UCLA Hematology/Oncology Santa Monica California
United States HonorHealth Research Institute Scottsdale Arizona
United States HonorHealth Scottsdale Shea Medical Center Scottsdale Arizona
United States Scottsdale Healthcare Hospitals DBA HonorHealth Scottsdale Arizona
United States Virginia G. Piper Cancer Pharmacy Scottsdale Arizona
United States Fred Hutchinson Cancer Center Seattle Washington
United States University of Washington Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Australia,  Korea, Republic of,  Slovakia,  Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Dose-limiting toxicities (DLT) for Dose Escalation and Dose Finding Baseline up to 28 Days (Cycle 1)
Primary Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities Baseline up to approximately 24 months
Primary Number of Participants With Adverse Events (AEs) According to Severity Baseline up to approximately 24 months
Primary Number of Participants With Adverse Events (AEs) According to Seriousness Baseline up to up to approximately 24 months
Primary Number of Participants With Adverse Events (AEs) by Relationship Baseline up to approximately 24 months
Primary Progression-Free Survival (PFS) for Dose Expansion The period from study entry until disease progression, death or date of last contact. Baseline up to 24 Months
Primary Objective Response Rate - Percentage of Participants With Objective Response in Dose Expansion Baseline up to 24 months
Primary Duration of Response (DR) for Dose Expansion Baseline up to 24 Months
Secondary PF-06940434 after multiple doses PK parameters (Cmax). Maximum observed plasma concentration of PF-06940434. Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).
Secondary Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434. Time zero extrapolated to the last quantifiable time point prior to the next dose. Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).
Secondary Systemic Clearance (CL) CL is a quantitative measure of the rate at which a drug substance is removed from the body. Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).
Secondary Volume of Distribution (Vd) Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).
Secondary Incidence and titers of anti-drug antibodies (ADA) against PF-06940434. Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).
Secondary Incidence and titers of neutralizing antibodies (NAb) against PF-06940434. Titers of neutralizing antibodies (NAb) against PF-06940434. Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days).
Secondary PK parameters of PF-06940434 and PF-06801591 (Cmax). Maximum observed plasma concentration after multiple doses of PF-06940434 and PD-1 (PF-06801591). Pre-dose on Cycle 1 Day 1 and on day 15 of Cycle 1; Day 1 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days)
Secondary Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434 and PF-06801591. Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434 and PF-06801591. Pre-dose on Cycle 1 Day 1 and on day 15 of Cycle 1; Day 1 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (each cycle is 28 days)
Secondary Characterize the multiple dose PK of PF-06940434 following intravenous administration in combination with PF-06801591. Maximum observed plasma concentration of PF-06940434. Cycle 4 Day 1 (each cycle is 28 days)
Secondary Area under the curve from time zero extrapolated to the last quantifiable dose of PF-06940434. Time zero extrapolated to the last quantifiable time point prior to the next dose. Cycle 4 Day 1 (each cycle is 28 days)
Secondary Number of participants with increased T-cells after PF-06940434 treatment. Pre-dose on Day 1 of Cycle 1; pre-dose on Day 1 of Cycles 2 and 3 (each cycle is 28 days)
Secondary Progression-Free Survival (PFS) for Dose Expansion The period from study entry until disease progression, death or date of last contact. Baseline to measured progression (up to approximately 24 months)
Secondary Duration of Response (DR) Baseline up to approximately 24 Months
Secondary Number of Participants With Objective Response for Dose Expansion portion Baseline up to 24 months
Secondary Disease Control Rate (DCR) DCR is defined as the percent of participants with a confirmed complete response (CR), partial response (PR) or stable disease (SD) according to RECIST 1.1. Every 8 weeks from the time of enrollment up to 2 years
Secondary Trough concentrations of PF-06940434 and PF-06801591 in Dose Expansion Day 1 of Cycle 1 though 4, Day 1 of every 2 Cycles starting from Cycle 5 up to 24 months (each cycle is 28 days). For Part 2 Cohort 3, Day 1 of Every Cycle (each cycle is 21 days)
Secondary Plasma Decay Half-Life (t1/2) Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Pre-dose on Cycle 1 Day 1 and on days 3, 8, and 15 of Cycle 1; Day 1 and Day 15 of Cycles 2 and 3; Days 1, 3, 8, and 15 of Cycle 4 and Pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days]
Secondary Incidence and titers of anti-drug antibodies (ADA) against PF-06801591 in Dose Finding and Dose Expansion Incidence and titers of anti-drug antibodies (ADA) against PF-06801591. Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days].
Secondary Incidence and titers of neutralizing antibodies (NAb) against PF-06801591 in Dose Finding and Dose Expansion. Incidence and titers of neutralizing antibodies (NAb) against PF-06801591. Pre-dose on Days 1 and 15 of Cycle 1, pre-dose on Day 1 of Cycles 2 and 3, pre-dose on Day 1 of Cycle 4, pre-dose on Day 1 of every cycle thereafter and at end of treatment (up to 24 Months) [each cycle is 28 days].
Secondary Overall Survival The period from study entry until death or date of last contact (24 months) From baseline to up to 2 years after last dose of study drug
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2